Trial Profile
A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Glycopyrrolate; Indacaterol; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms GLEAM; SHINE
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI111408).
- 24 Jul 2019 Results of pooled post hoc analysis of data from the ARISE (NCT01285492), SHINE (NCT01202188) and SPARK (NCT01120691) studies evaluating the efficacy of Indacaterol/glycopyrronium versus open label Tiotropium or glycopyrronium in COPD patients published in the Respirology
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.